GenEdit Rebrands As Breezebio, Raises $60M For Genetic Drug R&D
25 Feb 2026 //
FIERCE PHARMA
GenEdit Appoints Dr. Mora as CSO to Expand NanoGalaxy® Platform
13 Nov 2024 //
BUSINESSWIRE
GenEdit Announces Multiyear Collaboration and License Agreement with Genentech
23 Jan 2024 //
BUSINESSWIRE
Sarepta, GenEdit Share Progress Collaborate to Develop Gene Editing Therapeutics
01 Feb 2022 //
GLOBENEWSWIRE

Market Place
Sourcing Support